Crizotinib (PF-02341066)

Licensed by Pfizer Catalog No.S1068

Crizotinib (PF-02341066) Chemical Structure

Molecular Weight(MW): 450.34

Crizotinib (PF-02341066) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively.

Size Price Stock Quantity  
In DMSO USD 220 In stock
USD 110 In stock
USD 170 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 71 Publications

12 Customer Reviews

  • (c) Western blot analyses of p-Akt (Ser473) and p-S6RP (Ser235 and Ser236) in two RCT-E565 transplanted tumors treated with vehicle or PF02341066. Samples were isolated 4 h after the last dose from mice treated with PF02341066 for 3 d. (d) Responses of RCT-E565 transplanted tumors in athymic mice to PF02341066 or vehicle. Data are means ±s.e.m. (each group, n = 6). *P < 0.005, **P < 0.001 (Student,s t test).

    Nat Med 2011 17, 1116-1120. Crizotinib (PF-02341066) purchased from Selleck.

    Ba/F3 cells grown in the presence of IL-3, or Ba/F3 cells expressing native EML4-ALK (clone #2, #10, #101, and #155) and EML4-ALK L1196M (clone #216, #302, #303, and #355), were treated with CH5424802 or PF-02341066 for 48 hr, and then the viable cells were measured by the Cell Titer-Glo Luminescent Cell Viability Assay. IC50 values were determined by plotting the drug concentration versus percentage of cell growth inhibition. Data are shown as mean ±SD (n = 3).

     

     

    Cancer Cell 2011 19, 679–690. Crizotinib (PF-02341066) purchased from Selleck.

  • Mice bearing Ba/F3-EML4-ALK (clone #10) and EML4-ALK L1196M (clone #303) were administered vehicle, CH5424802 (60 mg/kg), or PF-02341066 (100 mg/kg) orally once daily for 8 days. Tumor volume for each dose group was measured. Data are shown as mean ± SD (n = 5). Parametric Dunnett’s test: ***p < 0.001; N.S., not significant, versus vehicle treatment at final day. For pharmacodynamic assay, mice bearing Ba/F3-EML4-ALK (clone #10) and -EML4-ALK L1196M (clone #303) were orally administered at single dose of vehicle, CH5424802 (60 mg/kg), or PF-02341066 (100 mg/kg), and the tumors were collected and lysed at 4 hr post-dosing. STAT3 and phosphorylated STAT3 (Tyr 705) were detected by immunoblot analysis using antibodies against each of them (n = 2 per group).

     

     

    Cancer Cell 2011 19, 679–690. Crizotinib (PF-02341066) purchased from Selleck.

    (A) Immunoblots of MPM cells treated with the indicated concentrations of crizotinib alone for 24 h with HGF stimulation.

    Sci Rep, 2016, 6:32992. Crizotinib (PF-02341066) purchased from Selleck.

  • Viability of Ba/F3 cells stably expressing DCTN1-ALK or EML4-ALK cDNAs after treatment with crizotinib (C). Ba/F3 cells transduced with lentiviral cDNA or empty vector were subjected to the assay, and the number of cells was counted at 72 hours.

    Oncologist, 2017, 22(2):158-164. Crizotinib (PF-02341066) purchased from Selleck.

    Combination of EGCG with c-MET inhibitor has enhanced inhibitory effects on the growth of OS cells. MG-63 and U-2OS cells were treated with crizotinib (0.05 mM) and/or EGCG (0.08 g/L) for 48 h, and the effects on cell apoptosis (b) were determined using flow cytometry. *P<0.05 versus the control; #P<0.05 versus crizotinib-treated groups or EGCG-treated groups

    Tumour Biol, 2016, 37(4):4373-82. Crizotinib (PF-02341066) purchased from Selleck.

  • (A) VimPro-Fluc activity in spheroids after 72-h treatment with control modulators of epithelial-mesenchymal transition (EMT) normalized to spheroid viability and compared to vimentin protein expression using Western blot analysis. (B) Dose-response curves for both U0126 and axitinib control modulators of EMT. RLU, relative luminescence units.

    J Biomol Screen 2011 16, 141-154. Crizotinib (PF-02341066) purchased from Selleck.

    Secondary assay development. The invasive potential of MDA-MB-231 spheroids was measured using modified Boyden chambers coated with Matrigel™. Invading cells were fixed, stained with DAPI, and quantified by fluorescence microscopy using 5 random fields per filter insert in triplicate. U0126, PF2341066, axitinib, and PKC412 inhibited the invasive potential of MDA-MB-231 spheroids by ~90% as compared to untreated spheroids (UT). ***p ≤ 0.001. IGF1R and dasatinib displayed no statistical difference as compared to UT MDA-MB-231 spheroids.

    J Biomol Screen 2011 16, 141-154. Crizotinib (PF-02341066) purchased from Selleck.

  • Crizotinib impaired tumor vascularization. a-e Representative photomicrographs (40×) of CD31 staining in negative control and indicated LFD, HFD, vehicle (veh) and crizotinib (criz) treated groups. b CD31 was quantified on 5–6 randomly selected regions of n = 2 sections each from each mouse. N = 9–10 mice (a vs b, Veh vs Criz, P = 0.0138)

    Springerplus, 2016, 5:348. Crizotinib (PF-02341066) purchased from Selleck.

    Inhibition of signaling pathway activation in lung tumor cell lines by kinase inhibitors. Lung tumor cells were cultured in 10% FBS until reaching ∼80% confluence and then the cells were starved in serum-free medium for overnight, followed by 4-hour treatment with the inhibitors. Cell lysates were then prepared and used for determination of the pathway activation signals by the CEER assay.

    Int J Proteomics 2011 2011, 215496. Crizotinib (PF-02341066) purchased from Selleck.

  • Inhibition of anchorage-independent growth of lung tumor cell lines by selected inhibitors. Each selected cell line was treated with the indicated inhibitor at 0.1 μM and 1 μM concentrations for two weeks and cell colony size formation was scored under the Nikon inverted-phase microscope.

    Int J Proteomics 2011 2011, Article ID 215496. Crizotinib (PF-02341066) purchased from Selleck.

    Western blot analysis of c-Met, MAPK and Akt. 0-100nM PF2341066 was added.

     

     

    Dr. Zhang of Tianjin Medical University. Crizotinib (PF-02341066) purchased from Selleck.

Purity & Quality Control

Choose Selective c-Met Inhibitors

Biological Activity

Description Crizotinib (PF-02341066) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively.
Targets
c-Met [1]
(A549, MDA-MB-231, GTL-16, HT29, 786-O, Colo-205, A498 cells)
ALK [1]
(Karpas299 cells)
11 nM 24 nM
In vitro

PF-2341066 displays similar potency against c-Met phosphorylation in mIMCD3 mouse or MDCK canine epithelial cells with IC50 of 5 nM and 20 nM, respectivly. PF-2341066 shows improved or similar activity against NIH3T3 cells engineered to express c-Met ATP-binding site mutants V1092I or H1094R or the P-loop mutant M1250T with IC50 of 19 nM, 2 nM and 15 nM, respectively, compared with NIH3T3 cells expressing wild-type receptor with IC50 of 13 nM. In contrast, a marked shift in potency of PF-2341066 is observed against cells engineered to express c-Met activation loop mutants Y1230C and Y1235D with IC50 of 127 nM and 92 nM, respectively, compared with wild-type receptor. PF-2341066 also potently prevents the phosphorylation of c-Met in NCI-H69 and HOP92 cells, with IC50 of 13 nM and 16 nM, respectively, which express the endogenous c-Met variants R988C and T1010I, respectively. PF-2341066 is >1,000-fold selective for the VEGFR2 and PDGFRβ RTKs, >250-fold selective for IRK and Lck, and ∼40- to 60-fold selective for Tie2, TrkA, and TrkB, all compared with c-Met. PF-2341066 is 20- to 30-fold selective for RON and Axl RTKs. In contrast, PF-2341066 shows a near-equivalent IC50 of 24 nM against the nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) oncogenic fusion variant of the ALK RTK expressed by the KARPAS299 human anaplastic large cell lymphoma (ALCL) cell line. PF-2341066 inhibits c-Met–dependent neoplastic phenotypes of cancer cells and angiogenic phenotypes of endothelial cells. PF-2341066 suppresses human GTL-16 gastric carcinoma cell growth with IC50 of 9.7 nM. PF-2341066 induces apoptosis in GTL-16 cells with IC50 of 8.4 nM. PF-2341066 inhibits HGF-stimulated human NCI-H441 lung carcinoma cell migration and invasion with IC50 of 11 nM and 6.1 nM, respectively. PF-2341066 inhibits MDCK cell scattering with IC50 of 16 nM. PF-2341066 prevents HGF-stimulated c-Met phosphorylation, cell survival, and Matrigel invasion with IC50 of 11 nM, 14 nM and 35 nM, respectively. In addition, PF-2341066 prevents serum-stimulated HMVEC branching tubulogenesis (formation of vascular tubes) in fibrin gels. [1] PF-2341066 also potently inhibits NPM-ALK phosphorylation in Karpas299 or SU-DHL-1 ALCL cells with an IC50 of 24 nM. PF-2341066 potently prevents cell proliferation, which is associated with G(1)-S-phase cell cycle arrest and induction of apoptosis in ALK-positive ALCL cells with IC50 of 30 nM, but not ALK-negative lymphoma cells. [2] Besides, PF-2341066 prevents osteosarcoma behavior associated with primary tumor growth (i.e., proliferation and survival) as well as metastasis (eg, invasion and clonogenicity). [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BAF3 NGDMdnVEgXSxdH;4bYMhSXO|YYm= NUfiSIRsPDhiaB?= MXHEUXNQ NVzrSWxUS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhSkGIMzDj[YxteyCneIDy[ZN{cW6pIFHMT{BHOTF5NFygcZV1[W62IHPv[ZhxemW|c3nu[{BGVUx2IIfpeIghUUN3MDDv[kAxNjZ{IN88US=> NXi2VnZTOjF3N{K1PFk>
BAF3 MV\DfZRwfG:6aXOgRZN{[Xl? M4L5TFQ5KGh? Mlr5SG1UVw>? MXzDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRWY{KGOnbHzzJIV5eHKnc4PpcochSUyNIFyxNVk3VSCvdYThcpQh[2:neIDy[ZN{cW6pIFXNUFQhf2m2aDDJR|UxKG:oIEKuNkDPxE1? NGTYPVkzOTV5MkW4PS=>
BAF3 NFPXe5ZEgXSxdH;4bYMhSXO|YYm= NVHjfXFvPDhiaB?= NUfmSWRGTE2VTx?= MXfDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRWY{KGOnbHzzJIV5eHKnc4PpcochTU2OND3BUGshf2m2aDDJR|UxKG:oIECuNlgh|ryP MkW4NlE2PzJ3OEm=
Kelly Mn;tR5l1d3SxeHnjJGF{e2G7 NWnrTZdGTE2VTx?= NHOwb5ZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBM\WyueTDj[YxteyCneIDy[ZN{cW6pIFHMT{BHOTF5NFygcZV1[W62IIfpeIghUUN3MDDv[kAxNjR{IN88US=> M13JNlIyPTd{NUi5
SH-SY5Y MVLDfZRwfG:6aXOgRZN{[Xl? MWXEUXNQ MUHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTTE1UYTW\IHPlcIx{KGW6cILld5NqdmdiQVzLJGYyOTd2TDDteZRidnRid3n0bEBKSzVyIH;mJFAvPTNizszN M2TMO|IyPTd{NUi5
SMS-KCN NFv1fHlEgXSxdH;4bYMhSXO|YYm= Ml7CSG1UVw>? MWTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTUXMuU0OQIHPlcIx{KGW6cILld5NqdmdiQVzLJHIyOjd3UTDteZRidnRid3n0bEBKSzVyIH;mJFAvQTFizszN MXKyNVU4OjV6OR?=
BAF3 Mn\ZR5l1d3SxeHnjJGF{e2G7 NET3T4Q1QCCq NHnDb5lFVVOR MVrDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRWY{KGOnbHzzJIV5eHKnc4PpcochXGWuLVHMT{B4cXSqIFnDOVAhd2ZiMD6xPUDPxE1? NVvpcoVUOjF3N{K1PFk>
3T3 NUPmcoR4TnWwY4Tpc44hSXO|YYm= MVqxJIg> NYC1fJJZTE2VTx?= NVeyOmVJUW6qaXLpeIlwdiCxZjDSU24h[XO|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIECuNFgh|ryP NYD4bnhSOjF6MUK0NVQ>
3T3-E NGPwXnlHfW6ldHnvckBCe3OjeR?= NV62SFlOOSCq NV35W|A5TE2VTx?= MVzJcohq[mm2aX;uJI9nKFSLRUKgZZN{\XO|ZXSg[5Jwf3SqIH\hZ5Rwei2rbnT1Z4VlKGG3dH;wbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFAvPDR6IN88US=> NWHRUGhsOjF6MUK0NVQ>
A549 MVjLbY5ie2ViQYPzZZk> Moi3NUBp M{nQ[WROW09? NEf6VFVKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IHOtUWVVKGurbnHz[UBmgHC{ZYPz[YQh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBJT0ZvaX7keYNm\CCjdYTvdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjByODFOwG0> NUfldW95OjF6MUK0NVQ>
BAF3-BCL NHjROoZHfW6ldHnvckBCe3OjeR?= M{XZTFEhcA>? MVHEUXNQ NV7ke5l3UW6qaXLpeIlwdiCxZjDBRmwh[XO|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIEGuNVU6KM7:TR?= MVGyNVgyOjRzNB?=
HEK293 NHT1N3FHfW6ldHnvckBCe3OjeR?= MmD2NUBp MlP1SG1UVw>? M37kZ2lvcGmkaYTpc44hd2ZiQWjMJIF{e2W|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkK5OEDPxE1? M4XPeFIyQDF{NEG0
HEK293 MVLGeY5kfGmxbjDBd5NigQ>? NXHFPIV2OSCq NEC5RoNFVVOR MnrHTY5pcWKrdHnvckBw\iCLUjDhd5Nme3OnZDDhd{Boem:5dHig[oFkfG:{LXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOi56OEeg{txO NX36PGZwOjF6MUK0NVQ>
Jurkat MnLaSpVv[3Srb36gRZN{[Xl? M2HNNlEhcA>? NEDDZW5FVVOR NVXiUY1oUW6qaXLpeIlwdiCxZjDMR2sh[XO|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIEKuO|QyKM7:TR?= NIHjOnEzOThzMkSxOC=>
KARPAS299 Mmm5T4lv[XOnIFHzd4F6 NYCwWlFnOSCq NHn0[GpFVVOR M1X6b2lvcGmkaYTpc44hd2ZiQVzLJIF{e2W|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkCyJO69VQ>? M4HUdVIyQDF{NEG0
PAE MVzGeY5kfGmxbjDBd5NigQ>? MmW3NUBp NXHMcVhWTE2VTx?= MoPMTY5pcWKrdHnvckBw\iCWUlvCJIF{e2W|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkO5PUDPxE1? M{D2bFIyQDF{NEG0
BAF3 NGrWOVVHfW6ldHnvckBCe3OjeR?= M1PaUFIuOyCm NEDuXmhFVVOR MlLBTY5pcWKrdHnvckBw\iCWRVyt[pV{\WRiaX7zeYxqdiC{ZXPldJRweiCneIDy[ZN{\WRid3n0bEBKSzVyIH;mJFEvPjR|IN88US=> NF3qc4kzOzd2MkK1Ni=>
KARPAS299 MUXDfZRwfG:6aXOgRZN{[Xl? M3zneVIuOyCm MV7EUXNQ NXn4b4ZiUUN3ME2wMlA3PDJizszN Mlu5NlM4PDJ{NUK=
EBC1 MnrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFm4cJY4OiCq M2W0XWROW09? NYPRWJBwUUN3ME2wMlAzOyEQvF2= MkTKNlM6QTN|Mki=
HCT116 NEHqfVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGn3d4c4OiCq M2TZSmROW09? MmLITWM2OD1zND64NkDPxE1? NEnKXnAzOzl7M{OyPC=>
MCF7 Mlz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTncII4OiCq MX;EUXNQ NXPSWmF6UUN3ME25MlU5KM7:TR?= NYfDNm53OjN7OUOzNlg>
MDA-MB-231 NHnWT4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVe3NkBp NGTBXopFVVOR NXrlfohZUUN3ME2xNE45KM7:TR?= Mlj5NlM6QTN|Mki=
MKN45 M1LNe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHxTIc4OiCq MknBSG1UVw>? MVPJR|UxRTBwMEGzJO69VQ>? M37uOFI{QTl|M{K4
NCI-H441 NGXtN5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXCfnY4OiCq MUXEUXNQ M4P5T2lEPTB;MUeuNlUh|ryP NV70ZXRUOjN7OUOzNlg>
NCI-H661 NWrrdnd{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\1O|IhcA>? Ml\RSG1UVw>? MWXJR|UxRTFzLkS3JO69VQ>? NH:3T44zOzl7M{OyPC=>
SK-MEL-28 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknzO|IhcA>? MYPEUXNQ NYnoTnBqUUN3ME2xNE46PyEQvF2= NVi4T5BNOjN7OUOzNlg>
SKOV3 NIHsZnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37wcVczKGh? Mn[wSG1UVw>? MluzTWM2OD1zMj64OUDPxE1? M{LkSlI{QTl|M{K4
SNU5 Mnz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnjO|IhcA>? MUfEUXNQ MXHJR|UxRTBwMEG2JO69VQ>? M4TEWFI{QTl|M{K4
NCI-H2228 NXnkXYlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrNNFY4OiCq MoD4SG1UVw>? NXfWVopIUW6qaXLpeIlwdiCxZjDBUGsu\nW|aX;uJIRzcX[nbjDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDBwMUG4JO69VQ>? MnmyNlQ1OzJ7MEm=
NCI-H3122 MmnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2r1N|czKGh? NHXVTpRFVVOR NUPQNmpzUW6qaXLpeIlwdiCxZjDBUGsu\nW|aX;uJIRzcX[nbjDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDBwMUC4JO69VQ>? NXXnVmJrOjR2M{K5NFk>
NCI-H3122 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDOVGc4OiCq M1\OXGROW09? NV\qNZQzUW6qaXLpeIlwdiCxZjDBUGsu\nW|aX;uJIRzcX[nbjDj[YxtKHC{b3zp[oVz[XSrb36gbY4hcHWvYX6gUmNKNUh|MUKyJINmdGy|IHjhdoJwemmwZzDBUGshTzF{NknBJI12fGGwdDD3bZRpKEmFNUCgc4YhOC54MkOg{txO MXOyOFQ{OjlyOR?=
NCI-H3122 M{HZVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fkOVczKGh? NF\mfmlFVVOR MlvpTY5pcWKrdHnvckBw\iCDTFut[pV{cW:wIHTybZZmdiClZXzsJJBzd2yrZnXyZZRqd25iaX6gbJVu[W5iTlPJMWg{OTJ{IHPlcIx{KGijcnLvdolv\yCDTFugUFEyQT[PIH31eIFvfCC5aYToJGlEPTBib3[gNE45OzhizszN MUKyOFQ{OjlyOR?=
NIH-3T3 NFHNXGdMcW6jc3WgRZN{[Xl? MmK1NUBp Mlv0SG1UVw>? NFr5S2xKdmirYnn0bY9vKG:oIHj1cYFvKHerbHSgeJlx\SCHTVy0MYZ2e2WmIFHMT{BmgHC{ZYPz[YQh[XO|ZYPz[YQh[XNicHjvd5Bpd3K7bHH0[YQhSUyNIHzleoVtKHerdHigTWM2OCCxZjCwMlA5KM7:TR?= MmXjNlQ1OzJ7MEm=
NIH-3T3 NVm4SlgzU2mwYYPlJGF{e2G7 M3rrS|EhcA>? M37NT2ROW09? NF;FRWRKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJGcyOjZ7QTDteZRidnRiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJJBpd3OyaH:tRWxMKGyndnXsJJdqfGhiSVO1NEBw\iByLk[wOUDPxE1? NUXuSZdHOjR2M{K5NFk>
NIH-3T3 NEPOPZNMcW6jc3WgRZN{[Xl? M2THfVEhcA>? M1LBOWROW09? NHeze5pKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJHMyOjB4WTDteZRidnRiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJJBpd3OyaH:tRWxMKGyndnXsJJdqfGhiSVO1NEBw\iByLk[yOkDPxE1? MoHGNlQ1OzJ7MEm=
NIH-3T3 NILmPFNMcW6jc3WgRZN{[Xl? NYnDXYp2OSCq NHHjVFhFVVOR MWrJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIFyxNVk3VSCvdYThcpQh\XiycnXzd4VlKGG|c3Xzd4VlKGG|IIDoc5NxcG9vQVzLJIxmfmWuIIfpeIghUUN3MDDv[kAxNjh2MzFOwG0> MkDRNlQ1OzJ7MEm=
NIH-3T3 NYC3[opRU2mwYYPlJGF{e2G7 NHO5[nAyKGh? M1HZcGROW09? MUfJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIFyxNVUzWiCvdYThcpQh\XiycnXzd4VlKGG|c3Xzd4VlKGG|IIDoc5NxcG9vQVzLJIxmfmWuIIfpeIghUUN3MDDv[kAyNjB{NjFOwG0> M{TjV|I1PDN{OUC5
BAF3 MlmzSpVv[3Srb36gRZN{[Xl? NIHLUIY4OiCq M4LSWGROW09? M3fVWWlvcGmkaYTpc44hd2ZiTmDNM2FNUyC2cnHud4Zm[3SnZDDhd5Nme3OnZDDhd{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIIfpeIghUUN3MDDv[kAxNjB3MTFOwG0> NUHVSYx2OjR2Nki2N|I>
BAF3 MnrLR5l1d3SxeHnjJGF{e2G7 Mo\hO|IhcA>? NHKwW|NFVVOR MofvTWM2OD1yLkm4JO69VQ>? MkXENlQ1Pjh4M{K=
NIH-3T3 MYnLbY5ie2ViQYPzZZk> MVmxJIg> M4DQO2lvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugSlEyPzSOIH31eIFvfCCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgdIhwe3Cqbz3BUGshdGW4ZXyge4l1cCCLQ{WwJI9nKDBwMU[1JO69VQ>? M2DsRlI1QDF7MUG2
NIH-3T3 NEPnOWRMcW6jc3WgRZN{[Xl? MWCxJIg> NEfZc4ZKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJGMyOTV4WTDteZRidnRiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJJBpd3OyaH:tRWxMKGyndnXsJJdqfGhiSVO1NEBw\iByLkS3PEDPxE1? NFrBTpEzPDhzOUGxOi=>
NIH-3T3 MlTST4lv[XOnIFHzd4F6 Mkn3NUBp NGLsRVJKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJGcyOjB{UjDteZRidnRiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJJBpd3OyaH:tRWxMKGyndnXsJJdqfGhiSVO1NEBw\iBzLkG0PEDPxE1? MoDENlQ5OTlzMU[=
NIH-3T3 M13y[mtqdmG|ZTDBd5NigQ>? NUjzboxEOSCq NEnsU2FKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJFEyPTGWaX7zJI12fGGwdDDlfJBz\XO|ZXSgZZN{\XO|ZXSgZZMheGixc4Doc{1CVEtibHX2[Ywhf2m2aDDJR|UxKG:oIEOuNFM6KM7:TR?= NX\6OG06OjR6MUmxNVY>
KARPAS299 M4Dx[mtqdmG|ZTDBd5NigQ>? NVjRflZKQTBibXnu NWTLNFVlTE2VTx?= M4jNeWlvcGmkaYTpc44hd2ZiTmDNMYZ2e2WmIFHMT{BxcG:|cHjvdplt[XSrb36g[ZhxemW|c3XkJJdqfGhiSVO1NEBw\iByLkGxJO69VQ>? NUHaO2YyOjR7MEC3OVA>
MKN 45 MmjFT4lv[XOnIFHzd4F6 MYmxJIg> M{\EfWROW09? M4HUcWlvcGmkaYTpc44hd2ZiYz3N[ZQheGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkCyJO69VQ>? NWfibWFLOjR7MEC3OVA>
A549 MUXDfZRwfG:6aXOgRZN{[Xl? MmXWOFghcA>? Mn;hSG1UVw>? MnzDTWM2OCCxZjC0MlA5PCEQvF2= MXqyOFkxODh|MB?=
NCI-H1975 Mke0R5l1d3SxeHnjJGF{e2G7 NVjxSolLPDhiaB?= M1K3VWROW09? MX\JR|UxKG:oIEeuOVUyKM7:TR?= M4fBbFI1QTByOEOw
NCI-H1993 MVTDfZRwfG:6aXOgRZN{[Xl? M2S2VlQ5KGh? MVHEUXNQ NETzPWFKSzVyIH;mJFAvODZzIN88US=> NEnPPY8zPDlyMEizNC=>
NCI-H1993 MYjBdI91d3OrczDBd5NigQ>? NHHaWYQyKM7:TR?= MUOyOEBp NXX6TGJoTE2VTx?= NVTaVFJ6\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppdy=> M{DRdlI1QTByOEOw
NIH-3T3 NX;pVWo4S3m2b4TvfIlkKEG|c3H5 NEHMWXg1QCCq NXO4XmE3TE2VTx?= Mkj6TWM2OCCxZjCwMlM3PCEQvF2= NEK0[pgzPDlyMEizNC=>
EBC1 MoHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\qO|IhcA>? MX;EUXNQ NXPyRmlyUUN3MDDv[kAxNjByNkmg{txO NYPjPJkxOjR7MEC4N|E>
KARPAS299 M3T6TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\xUlczKGh? Mn;1SG1UVw>? NXz0UZZ7UUN3MDDv[kAxNjJizszN MXSyOFkxODh|MR?=
NB1 M1fkOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLqbmJuUUN3ME25NU46QCCwTR?= MUfTRW5ITVJ?
NCI-SNU-5 NXLEUnRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TXe2lEPTB;MUC1Mlc2KG6P NYTnR5ZiW0GQR1XS
SR NG\RcY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTF{Nj6zNUBvVQ>? M2PFfXNCVkeHUh?=
SF539 NIPuTHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3uwZWlEPTB;MkC0MlI1KG6P NGPUS3JUSU6JRWK=
SU-DHL-1 NUTE[3hOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUe1dmRyUUN3ME2zN|YvQDJibl2= MkP1V2FPT0WU
SCC-3 NYi4[ZZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYP5[5FxUUN3ME2zOVYvPzZibl2= Mny2V2FPT0WU
DEL MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTN4OT65JI5O NXzpZodyW0GQR1XS
CTV-1 M1jFWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLEUHp3UUN3ME21PVYvPDhibl2= MWTTRW5ITVJ?
EM-2 NEDKcXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnL2TWM2OD14MEGuN|Qhdk1? MXTTRW5ITVJ?
MHH-CALL-2 M1vpUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PtbmlEPTB;NkiyMlU4KG6P MWTTRW5ITVJ?
KM12 M1K5Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHOXo9UUUN3ME23NFYvQSCwTR?= NVOxWI5OW0GQR1XS
KINGS-1 NULzOZl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojNTWM2OD15NEmuO|Uhdk1? NGLJWW5USU6JRWK=
MEG-01 NVzqfoN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILDU3FKSzVyPUi1O{43PiCwTR?= M2XqTXNCVkeHUh?=
BV-173 NUXsZpFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTFwMEW5PVch|ryP M4HrZnNCVkeHUh?=
LAMA-84 NVfXN4k1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDJWplRUUN3ME2xMlM5Ojh{IN88US=> NE\ST4JUSU6JRWK=
KARPAS-299 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LJXWlEPTB;MT60NFg3OSEQvF2= NXjNVnBTW0GQR1XS
K-562 NH;iO5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrLTWM2OD1zLkeyNlY6KM7:TR?= NV3sZmtGW0GQR1XS
SK-LMS-1 NGTYSnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\iZ2lEPTB;MT63Olg3PyEQvF2= MnPlV2FPT0WU
MOLT-16 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjsPGhKSzVyPUGuPVU2PzVizszN Mn7uV2FPT0WU
CMK NF7ReJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrMSId6UUN3ME2xMlk3OTV7IN88US=> Mmr5V2FPT0WU
ST486 NYfFWWw3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXRRnVUUUN3ME2yMlQ{ODd|IN88US=> NE\GUZpUSU6JRWK=
CI-1 NVrmfJc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTJwNEm2OVkh|ryP MlPYV2FPT0WU
KP-N-RT-BM-1 NWrv[5lbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DQb2lEPTB;Mj63NFEzOiEQvF2= MV7TRW5ITVJ?
ALL-PO NEjKcZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTNwMUiyNFch|ryP NV3h[WxYW0GQR1XS
KS-1 NHjMZlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rYRmlEPTB;Mz6yNVIzPSEQvF2= NULZVVBXW0GQR1XS
Becker NEP0[GtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7YdnlDUUN3ME20MlI{QTNizszN NHH6U5BUSU6JRWK=
GDM-1 NWXpVW9oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\1OGlEPTB;ND6yOFYyPyEQvF2= MnXNV2FPT0WU
BC-1 NYPwOnQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLwTWM2OD12LkS5Nlc4KM7:TR?= MVTTRW5ITVJ?
NB14 MnrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjxXZQ4UUN3ME20Mlg{PTJ2IN88US=> NX;1fG5uW0GQR1XS
NOS-1 MnjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV:xV2NiUUN3ME21MlM{QDd2IN88US=> Mm\vV2FPT0WU
MZ1-PC NGHjSXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoL3TWM2OD13LkiyNVUyKM7:TR?= NEWyXIlUSU6JRWK=
A498 MoXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTE[mVXUUN3ME22MlA5PDd|IN88US=> M{nvbnNCVkeHUh?=
EW-16 M4nyXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{GxRmlEPTB;Nj6zO|c4OyEQvF2= M4HXcXNCVkeHUh?=
NALM-6 NHfkNW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTZwNkizPFch|ryP NWnEdlYzW0GQR1XS
EB-3 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIGweGVKSzVyPUeuNFczOzNizszN M3nNbXNCVkeHUh?=
697 NXLrWppCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmC4TWM2OD17LkK0N|I6KM7:TR?= Mlm0V2FPT0WU
Ramos-2G6-4C10 NXztO415T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVX3XFJHUUN3ME25MlU6QDR{IN88US=> NGnmOVFUSU6JRWK=
KNS-81-FD NVjlbnM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XjcmlEPTB;OT62PVY2OyEQvF2= MV7TRW5ITVJ?
HUTU-80 NYTXWmk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlG4TWM2OD17Lke0OlQzKM7:TR?= M2PjeXNCVkeHUh?=
LS-411N M124OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPaVY5KSzVyPUGwMlA2PjdizszN MVzTRW5ITVJ?
RPMI-8402 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlX5TWM2OD1zMD6xNVYh|ryP MWnTRW5ITVJ?
KU812 MmXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVT6UIY6UUN3ME2xNE4zQTlzIN88US=> MXfTRW5ITVJ?
EW-1 NX3IOJZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;iTWM2OD1zMD60OFI2KM7:TR?= NYLUT5M3W0GQR1XS
HC-1 MnH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfjVHpKUUN3ME2xNE41QDR2IN88US=> M3H2R3NCVkeHUh?=
NB69 NYW2ZlhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fmWmlEPTB;MUCuOVA1OyEQvF2= MUDTRW5ITVJ?
MFH-ino MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGq3[mpKSzVyPUGwMlg{ODNizszN M3[5[nNCVkeHUh?=
CCRF-CEM NX\Db5hxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvYNWdKSzVyPUGxMlU6PyEQvF2= NVPqd5RzW0GQR1XS
SK-N-DZ NEX4WWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnJXlVKSzVyPUGyMlA1OzZizszN NVPKRYh3W0GQR1XS
NCI-H720 M33UNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrqTWM2OD1zMj6xO|A2KM7:TR?= MmPnV2FPT0WU
HCC1187 NU\ISYZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDpTYNvUUN3ME2xNk4zODRzIN88US=> NXfhXFU4W0GQR1XS
IST-SL2 NHjHb3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17WV2lEPTB;MUKuOFg4OiEQvF2= Ml7vV2FPT0WU
KE-37 MnnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1n4NGlEPTB;MUKuO|k3PiEQvF2= NF72Z3hUSU6JRWK=
HCC1599 M{PFV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2Dpe2lEPTB;MUKuPVA3QSEQvF2= NIHPNVRUSU6JRWK=
A4-Fuk MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX6yO5pxUUN3ME2xNk46PTh4IN88US=> NE\BellUSU6JRWK=
NKM-1 NFO1O|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTF|LkK5NlUh|ryP NHjFWmJUSU6JRWK=
BE-13 MoXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPDTWM2OD1zMz63PVg6KM7:TR?= NV65eWtDW0GQR1XS
MV-4-11 NIfM[ZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\rb2lEPTB;MUSuNFMzPCEQvF2= NYfBemVGW0GQR1XS
OPM-2 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIL3dXBKSzVyPUG0MlQxQDVizszN M2[1T3NCVkeHUh?=
KARPAS-422 NEL0Zo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3n1c2lEPTB;MUSuOVEzPiEQvF2= Ml76V2FPT0WU
RPMI-8226 NXjEcmdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPiN2VKSzVyPUG0Mlg6OTVizszN NX3hTYZ2W0GQR1XS
KARPAS-45 NUfqZXdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvnN2IxUUN3ME2xOU44PzF4IN88US=> MXHTRW5ITVJ?
SK-PN-DW MoHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLqTWM2OD1zNT64OlMyKM7:TR?= MXzTRW5ITVJ?
LC-2 M1\z[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTF4LkG1NFYh|ryP NX7Sd2FWW0GQR1XS
NCI-H1648 NISxfXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTF4LkK1OEDPxE1? NYWzVmVUW0GQR1XS
RL95-2 Mn;WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjNb5FKSzVyPUG2MlM6PzhizszN M{D4d3NCVkeHUh?=
KNS-42 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mly4TWM2OD1zNj63Nlc1KM7:TR?= NY\pcWpYW0GQR1XS
RPMI-6666 NVXEOoh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUmwb3N{UUN3ME2xOk46OjFzIN88US=> NXXEcmh7W0GQR1XS
SIG-M5 NU\xZoo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{[2SGlEPTB;MUeuNVkxOyEQvF2= MVzTRW5ITVJ?
VA-ES-BJ MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3:1NGlEPTB;MUeuO|Q2OSEQvF2= MkHCV2FPT0WU
MONO-MAC-6 MkC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3XcYV{UUN3ME2xO{46OzF{IN88US=> M33BUHNCVkeHUh?=
LAN-6 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\YTWM2OD1zOD63OVU4KM7:TR?= MX7TRW5ITVJ?
A388 MlKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljNTWM2OD1zOT6zNFU6KM7:TR?= MWfTRW5ITVJ?
SK-NEP-1 M2r2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTJyLkKxN|Ih|ryP NFnqeoRUSU6JRWK=
TE-10 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTJyLkWyNlEh|ryP M1\COnNCVkeHUh?=
HL-60 M4q4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7oO5ByUUN3ME2yNE46ODl7IN88US=> NWjzd49[W0GQR1XS
MC116 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mom4TWM2OD1{MT63NlIyKM7:TR?= M{DjVnNCVkeHUh?=
SW962 MoTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXKxVoYxUUN3ME2yNU44QTF3IN88US=> NITZR2ZUSU6JRWK=
NOMO-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;nWpJsUUN3ME2yNk43PTZ2IN88US=> Mnu3V2FPT0WU
CTB-1 Mon4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljFTWM2OD1{Mj64OlcyKM7:TR?= M2\ZdHNCVkeHUh?=
MRK-nu-1 M4q3cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLKTWM2OD1{Mj65NFc1KM7:TR?= NH2yNlBUSU6JRWK=
GR-ST M1jaUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTJ|Lke2JO69VQ>? NHPPU2ZUSU6JRWK=
HH MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFP5N3BKSzVyPUK0MlAxOyEQvF2= Mnz1V2FPT0WU
NCI-H1963 MmXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\MW2lEPTB;MkSuNFc5OiEQvF2= NHfR[IVUSU6JRWK=
QIMR-WIL NFv5VolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITy[WtKSzVyPUK0Mlg4PzJizszN Ml3uV2FPT0WU
CGTH-W-1 M1TSXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1Tx[GlEPTB;MkWuNFczOyEQvF2= NV\oe2hvW0GQR1XS
LP-1 MnfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnZ[5pKSzVyPUK1MlY2PTFizszN MYnTRW5ITVJ?
NCI-H748 M1HlNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDuOFVKSzVyPUK2MlUyOzdizszN MlGwV2FPT0WU
PF-382 NHnkTo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3i[Y1KSzVyPUK3MlIzOjNizszN NFXx[3RUSU6JRWK=
ATN-1 Mm\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfaTWM2OD1{Nz6zO|MzKM7:TR?= Mln1V2FPT0WU
L-540 M1vzTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYO4c3ByUUN3ME2yO{43PDV7IN88US=> NG\2W|ZUSU6JRWK=
LXF-289 M3;5[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfnVJdKSzVyPUK3Mlc2OTlizszN NF3LSGVUSU6JRWK=
LS-513 NXLDXYVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTJ6LkG4NFch|ryP MmHLV2FPT0WU
NCI-H1581 NUT1bG1IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVr6[lJFUUN3ME2zNE4{QTd4IN88US=> NYftfJdZW0GQR1XS
ES6 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XuVWlEPTB;M{CuOlg6QSEQvF2= NXnvU|BSW0GQR1XS
SW982 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3oWHdyUUN3ME2zNE45PTZ4IN88US=> NX7ueZNXW0GQR1XS
DOHH-2 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVyyS3JYUUN3ME2zNU42QDl|IN88US=> MYLTRW5ITVJ?
DB M3;OT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4L1cWlEPTB;M{OuPVQ{OSEQvF2= MWjTRW5ITVJ?
MPP-89 M{TsbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3NUWlKSzVyPUO0MlE4PTZizszN M3\3XHNCVkeHUh?=
LB831-BLC Moj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkToTWM2OD1|ND61NVg1KM7:TR?= M3;QTHNCVkeHUh?=
NB5 M3fHZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk[0TWM2OD1|ND64OVM2KM7:TR?= Mn3aV2FPT0WU
GB-1 MoPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnG[FZ6UUN3ME2zOU4xPDZ7IN88US=> MXXTRW5ITVJ?
TE-15 NVOzW2NRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXwVZZyUUN3ME2zOU4zOjN6IN88US=> NFfOVZFUSU6JRWK=
LC4-1 M1\ZdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jVW2lEPTB;M{WuN|g1PyEQvF2= NUXyO4ZGW0GQR1XS
NCI-H747 M{P2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWCzRmUyUUN3ME2zOk4yOzZ7IN88US=> NIfPc3ZUSU6JRWK=
NTERA-S-cl-D1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLTdVNYUUN3ME2zPE44OzR5IN88US=> NHjFfGRUSU6JRWK=
SK-MM-2 NFTKRXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrBWZZKSzVyPUSwMlEyPDZizszN MYDTRW5ITVJ?
TGW M2LmOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlr1TWM2OD12MT6wOVY{KM7:TR?= NWq0[JU4W0GQR1XS
ONS-76 M{nvNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYKwOGZIUUN3ME20Nk41QDh|IN88US=> MYDTRW5ITVJ?
CPC-N MmTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTR{Lkm5O|Eh|ryP MYrTRW5ITVJ?
ES4 MorjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTx[|Y{UUN3ME20OE41OTV|IN88US=> M4LwVXNCVkeHUh?=
Daudi M3TW[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\KN2lEPTB;NEWuNFgzPyEQvF2= NFTZV4hUSU6JRWK=
MOLT-4 Mme5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTR3LkC4OVMh|ryP NF7iUGJUSU6JRWK=
HT-144 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWS2NFMyUUN3ME20Ok44OjZizszN MVjTRW5ITVJ?
SW872 NWTEZlhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHIXlFKSzVyPUS4MlE6OzNizszN NVPJPIpDW0GQR1XS
D-283MED MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTR6LkO1OFIh|ryP NYjQfGo3W0GQR1XS
NCI-H2126 MkOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvseFFXUUN3ME20PE45PDd4IN88US=> NEDZN3lUSU6JRWK=
NCI-SNU-16 NXz6V29sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\0XGlEPTB;NEmuNlE1OyEQvF2= MVjTRW5ITVJ?
CESS NHrFOYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{e4[2lEPTB;NEmuOVA5QCEQvF2= MlrwV2FPT0WU
A101D NYO2RZJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTR7Lkm3N|Yh|ryP MXnTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo In the GTL-16 model, PF-2341066 reveals the ability to cause marked regression of large established tumors (>600 mm3) in both the 50 mg/kg/day and 75 mg/kg/day treatment cohorts, with a 60% decrease in mean tumor volume over the 43-day administration schedule. In an another study, PF-2341066 displays the ability to completely inhibits GTL-16 tumor growth for >3 months, with only 1 of 12 mice exhibiting a significant increase in tumor growth over the 3-month treatment schedule at 50 mg/kg/day. In the NCI-H441 NSCLC model, a 43% decrease in mean tumor volume is observed at 50 mg/kg/day during the 38-day PF-2341066 administration cycle. In the Caki-1 RCC model, a 53% decrease in mean tumor volume is observed to be associated with decreased volume of each tumor by at least 30% at 50 mg/kg/day during the 33-day PF-2341066 administration cycle. PF-2341066 also reveals near-complete prevention of the growth of established tumors at 50 mg/kg/day in the U87MG glioblastoma or PC-3 prostate carcinoma xenograft models, with 97% or 84% inhibition on the final study day, respectively. In contrast, PF-2341066 p.o. given at 50 mg/kg/day does not significantly inhibit tumor growth in the MDA-MB-231 breast carcinoma model, or the DLD-1 colon carcinoma model. A significant dose-dependent reduction of CD31–positive endothelial cells is observed at 12.5 mg/kg/day, 25 mg/kg/day, and 50 mg/kg/day in GTL-16 tumors, indicating that inhibition of MVD shows a dose-dependent correlation to antitumor efficacy. PF-2341066 displays a significant dose-dependent reduction of human VEGFA and IL-8 plasma levels in both the GTL-16 and U87MG models. Marked inhibition of phosphorylated c-Met, Akt, Erk, PLCλ1, and STAT5 levels is observed in GTL-16 tumors following p.o. administration of PF-2341066.[1] P.o. administration of PF-2341066 to severe combined immunodeficient-Beige mice bearing Karpas299 ALCL tumor xenografts leads to dose-dependent antitumor efficacy with complete regression of all tumors at the 100 mg/kg/d dose within 15 days of initial compound administration. In addition, inhibition of key NPM-ALK signaling mediators, including phospholipase C-gamma, signal transducers and activators of transcription 3, extracellular signal-regulated kinases, and Akt by PF-2341066 are observed at concentrations or dose levels, which correlated with inhibition of NPM-ALK phosphorylation and function.[2] PF-2341066 prevents osteosarcoma behavior associated with primary tumor growth (eg, proliferation and survival) as well as metastasis (eg, invasion and clonogenicity). In nude mice treated with PF-2341066 via oral gavage, the growth and associated osteolysis and extracortical bone matrix formation of osteosarcoma xenografts are prevented by PF-2341066.[3] Treatment of c-MET-amplified GTL-16 xenografts with 50 mg/kg PF-2341066 elicits tumor regression that is associated with a slow reduction in 18F-FDG uptake and decreases expression of the glucose transporter 1, GLUT-1.[4]

Protocol

Kinase Assay:

[1]

+ Expand

Cellular kinase phosphorylation ELISA assays:

Cells are seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 h. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors are added for up to 20 min. After incubation of cells with PF-2341066 for 1 h and/or appropriate ligands for the designated times, cells are washed once with HBSS supplemented with 1 mM Na3VO4, and protein lysates are generated from cells. Subsequently, phosphorylation of selected protein kinases is assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates are (a) incubated in the presence of protein lysates at 4°C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase–conjugated anti–total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3′,5,5′-tetramethyl benzidine peroxidase substrate to initiate a colorimetric reaction that is stopped by adding 0.09 N H2SO4; and (f) measured for absorbance in 450 nm using a spectrophotometer.
Cell Research:

[1]

+ Expand
  • Cell lines: GTL-16 gastric carcinoma cells and T47D breast carcinoma cells
  • Concentrations: 0-256 nM
  • Incubation Time: 1 hour
  • Method:

    Cells including GTL-16 gastric carcinoma cells and T47D breast carcinoma cells are seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 hours. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors are added for up to 20 minutes. After incubation of cells with PF-2341066 for 1 hour and/or appropriate ligands for the designated times, cells are washed once with HBSS supplemented with 1 mM Na3VO4, and protein lysates are generated from cells. Subsequently, phosphorylation of selected protein kinases is assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates are (a) incubated in the presence of protein lysates at 4 °C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase–conjugated anti–total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3,5,5-tetramethyl benzidine peroxidase substrate to initiate a colorimetric reaction that is stopped by adding 0.09 N H2SO4; and (f) measured for absorbance in 450 nm using a spectrophotometer.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Female or male nu/nu mice bearing NCI-H441,or DLD-1, or MDA-MB-231
  • Formulation: --
  • Dosages: 12.5 mg/kg/day, 25 mg/kg/day, and 50 mg/kg/day
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 9 mg/mL (19.98 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
5% DMSO+30% PEG 300+dd H2O
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 450.34
Formula

C21H22Cl2FN5O

CAS No. 877399-52-5
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03052608 Not yet recruiting Carcinoma, Non-Small-Cell Lung Pfizer March 2017 Phase 3
NCT02838420 Recruiting Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer Hoffmann-La Roche August 2016 Phase 3
NCT02836847 Recruiting Cholangiocarcinoma of the Extrahepatic Bile Duct|Gallbladder Cancer Shanghai Jiao Tong University School of Medicine|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Ruijin Hospital|RenJi Hospital|Eastern Hepatobiliary Surgery Hospital|Huashan Hospital July 2016 Phase 2
NCT02946359 Recruiting Lung Adenocarcinoma Metastatic Chinese PLA General Hospital July 2016 Phase 2
NCT02679170 Recruiting Non-Small Cell Lung Cancer Pfizer June 2016 --
NCT02767804 Recruiting Non-small Cell Lung Cancer Xcovery Holding Company, LLC June 2016 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Could you tell me whether this product represents the pure R-form of crizotinib, or is the the racemic Crizotinib, so a mixture of the S- and the R-form?

  • Answer:

    Our S1068 Crizotinib is R enantiomer(except batch 05 and 06, they are racemate), and S7505 is S enantiomer.

c-Met Signaling Pathway Map

c-Met Inhibitors with Unique Features

Related c-Met Products

Tags: buy Crizotinib (PF-02341066) | Crizotinib (PF-02341066) supplier | purchase Crizotinib (PF-02341066) | Crizotinib (PF-02341066) cost | Crizotinib (PF-02341066) manufacturer | order Crizotinib (PF-02341066) | Crizotinib (PF-02341066) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID